The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.
The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
LifeOmic, founded less than a year ago, expects omic data sets to become as clinically relevant as diagnostic medical imaging.
The La Jolla, California-based firm is moving beyond its US home market into other regions that promise growth for synthetic genomics providers.
The new division will enable BGI to expand partnerships with universities, companies, and health and agriculture-related organizations, among other things.
The company will focus on gaining customers for its custom and pre-defined hybrid capture kits first in Southern California, and then across the US.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.